HemoBioTech's Human Blood Substitute, HemoTech, Highlighted in Scientific American Online
Posted on: Tuesday, 20 November 2007, 09:01 CST
HemoBioTech, Inc.'s (OTCBB: HMBT, http://www.hemobiotech.com), HemoTech, potentially the first viable substitute for human blood, was highlighted in the November 13, 2007 online edition of Scientific American as the lead story in its news section.
The full text of the article, entitled "New Blood Substitutes Promise Relief For Sagging Blood Banks," notes that HemoTech "not only suppresses hemoglobin's inherent toxicity, but also serves to improve blood flow and even spur the creation of new red blood cells." Other products using hemoglobin or perfluorocarbon compounds as blood substitutes have shown toxicity problems in their clinical trials. The article's placement is especially timely, given that it comes shortly after HemoBioTech announced taking critical steps necessary for initiating trials in India. The goal is for such trials to run in parallel with trials in the United States. The Scientific American online article is available by clicking here, www.sciam.com/article.cfm?id=blood-substitutes-hemoglobin-anemia.
"We are pleased that Scientific American online has taken note of HemoBioTech's progress with HemoTech and the benefits it could provide the world," said Arthur Bollon, PhD, Chairman and Chief Executive Officer of HemoBioTech. "The extraordinary potential advantages discussed in the article are a result of the patented chemical method used to create HemoTech. We remain focused on our goal of extending the initial clinical trial of HemoTech in order to move us closer to one day being able to satisfy a major need in the broad blood use market."
About Scientific American
Scientific American is a popular-science magazine, published (first weekly and later monthly) since August 28, 1845, making it the oldest continuously published magazine in the United States. It brings articles about new and innovative research to the amateur and lay audience. In March 1996 Scientific American launched its own website at SciAm.com.
About HemoBioTech, Inc.
HemoBioTech is working on the development and commercialization of HemoTech, a novel human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. HemoTech is composed of bovine hemoglobin that is chemically modified with adenosine triphosphate, adenosine, and glutathione. In addition to carrying oxygen through the bloodstream, HemoTech also induces erythropoiesis (red blood cell production). Based on preclinical studies and an initial foreign human clinical study, the company believes that HemoTech, due to its novel chemical composition, may significantly diminish or even eliminate the intrinsic toxicities that have plagued other attempts at developing blood substitutes. HemoTech is currently undergoing additional studies to confirm and possibly expand on these results. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, surgery, and other conditions. Corporate headquarters are located at 5001 Spring Valley Road, Suite 1040-West, Dallas, Texas 75244. For further information visit our website at http://www.hemobiotech.com.
Safe Harbor Statement
Except for historical information, the matters discussed in this news release may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief, or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre-clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTech's Annual Report on Form 10-KSB for the year ended December 31, 2006, as amended, and HemoBioTech's other reports filed with the Securities and Exchange Commission.
Source: Business Wire
Related Articles
- XenoPort Announces Positive Results of a Phase 1 Clinical Trial of XP21279
- XenoPort Announces Initiation of Clinical Trials
- XenoPort Announces Results of a Phase 1 Clinical Trial and Plans for Additional Phase 2 Clinical Trials of XP19986
- Cytokinetics Announces Presentation of Phase I Clinical Trial Data for CK-1827452 During Recent and Late Breaking Trials Session at the 2006 Heart Failure Society of America Annual Meeting
- University of Cincinnati and CardioVascular BioTherapeutics to Host Reunion Celebration for Patients Involved in Phase I Clinical Trial
- CytRx Reports Successful Completion of Phase I HIV Vaccine Clinical Trial
- Cytokinetics Announces Positive Phase I Clinical Trial Results for CK-1827452
- Diovan(R) (Valsartan) the First Blood Pressure Medication in a Large-Scale Clinical Trial to Lower C-Reactive Protein, an Important Marker of Inflammation
- XenoPort Initiates a Phase 2a Clinical Trial of XP19986 As a Treatment for Gastroesophageal Reflux Disease
- Cytokinetics Provides Clinical Trials Update for Ispinesib (SB-715992)
 |
 |
User Comments (0)
RSS Feeds